Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A team of NDORMS researchers, experienced physiotherapists and patient representatives got together for a one day meeting in Oxford to develop the physiotherapy exercise intervention for a recently funded NIHR Health Technology Assessment (HTA) Programme trial called GRASP (Getting it Right: Addressing Shoulder Pain) which is looking at the best treatments for shoulder pain in patients with a rotator cuff disorder.

Shoulder pain is very common and rotator cuff disorders are the most common type of shoulder pain, accounting for 70% of all new cases. Common treatments include advice, rest, painkillers, physiotherapy and steroid injections. Although used quite often, the effectiveness of physiotherapy is unclear. There is uncertainty about which techniques are most effective, how they should be delivered and whether an injection, in addition to exercise, may be of more benefit. We have been commissioned by the NIHR HTA Programme (15/26/06) to conduct a randomised trial that aims to give a definitive answer to find the best treatments for rotator cuff disorders in primary care.

The GRASP trial is due to start in October 2016 and we plan to recruit 704 participants with a new episode of shoulder pain, attributable to a rotator cuff disorder, across at least eight musculoskeletal services and their related physiotherapy services in the UK. The study is being led by Professor Sallie Lamb and Dr Sally Hopewell.


If you are interested in knowing more, please contact the GRASP Trial Team: GRASP@ndorms.ox.ac.uk. Further information will be available soon on the OCTRU website.

Similar stories

Celebrating Clinical Trials Day at NDORMS

To mark Clinical Trials Day we take a look at some of the recent developments at NDORMS and celebrate the teams that make this important area of our research programme possible.

Breakthrough in treatment for Dupuytren’s disease

Injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules is effective in reducing nodule hardness and nodule size.

Liposomal bupivacaine found to be no more effective than current treatments for post-operative knee pain

A new study published in JAMA, has found that a drug recently licensed in the UK has no effect on post-operative knee replacement recovery or pain, compared to the current treatment when administered at site of surgery.

Cemented hip replacement improves quality of life for patients over 60

The White 5 trial compared implants fixed with bone cement against uncemented implants for hip fractures treated with hemiarthroplasty.

FUTURE-GB looking ahead to 2022

FUTURE-GB has bounced into 2022 ahead of both predicted recruitment into Stage 2 (the Randomised Controlled Trial), and the sites open in Stage 2! Congratulations to all our sites for their hard work so far.